Xenome gets acute

By Kate McDonald
Wednesday, 19 November, 2008

Private Brisbane biotech Xenome has expanded its protein chemistry portfolio by licensing peptide technology from Flinders University.

The IP relates to two peptides identified by Flinders researchers as candidates for blocking cell surface receptors involved in acute pancreatitis.

The receptors are activated by the peptide galanin, normally involved in the regulation of the release of neurotransmitters and hormones.

Xenome, which is in early stage trials of cone shell based venom peptides for acute and chronic pain, will pay Flinders milestone payments and royalties. It plans to modify the structure of the peptides to develop their capabities as drug candidates.

Related News

RSV immunisation program for babies slashes hospital stays

An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...

A targeted treatment option for psoriasis

New research from MedUni Vienna paves the way for the development of a therapy that not only...

Maternal cannabis use puts kids at risk of behavioural problems

Children exposed to their mother's cannabis use during pregnancy and after birth are three...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd